MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Sells 3,149 Shares of DaVita Inc. (NYSE:DVA)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH cut its stake in shares of DaVita Inc. (NYSE:DVA) by 7.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,206 shares of the company’s stock after selling 3,149 shares during the quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in DaVita were worth $5,412,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. purchased a new stake in shares of DaVita in the fourth quarter worth $30,000. Principal Securities Inc. purchased a new stake in DaVita in the 4th quarter worth $37,000. GAMMA Investing LLC bought a new stake in DaVita during the fourth quarter valued at about $60,000. Quest Partners LLC purchased a new position in shares of DaVita in the fourth quarter valued at about $74,000. Finally, Federated Hermes Inc. boosted its stake in shares of DaVita by 1,284.4% in the third quarter. Federated Hermes Inc. now owns 1,246 shares of the company’s stock worth $118,000 after acquiring an additional 1,156 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Price Performance

Shares of DVA stock traded down $0.16 on Tuesday, reaching $138.45. The company’s stock had a trading volume of 668,494 shares, compared to its average volume of 874,251. The company has a market capitalization of $12.14 billion, a price-to-earnings ratio of 15.68, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96. The stock’s fifty day simple moving average is $139.83 and its 200-day simple moving average is $127.09. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $147.93.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. The firm had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.58 EPS. Analysts forecast that DaVita Inc. will post 9.62 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Barbara J. Desoer sold 5,030 shares of the stock in a transaction on Friday, May 10th. The stock was sold at an average price of $138.81, for a total transaction of $698,214.30. Following the sale, the director now owns 10,954 shares in the company, valued at approximately $1,520,524.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Barclays boosted their price target on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a report on Monday, May 6th. Truist Financial raised their target price on shares of DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, May 15th. Finally, StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $144.67.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.